ZK824859 10mg | ≥98%
CSNpharm
ZK824859 is a new structural class uPA inhibitor with potential effect on treating multiple sclerosis.
More Information Supplier Page
ZK824859 is a new structural class uPA inhibitor with potential effect on treating multiple sclerosis.
More Information Supplier Page
ZK824859 is a new structural class uPA inhibitor with potential effect on treating multiple sclerosis.
More Information Supplier Page
Roflumilast N-oxide, an active metabolite of roflumilast, is an inhibitor of phosphodiesterase 4 (PDE4). It can be combined with formoterol to enhance the antiinflammatory effect of dexamethasone.
More Information Supplier Page
Roflumilast N-oxide, an active metabolite of roflumilast, is an inhibitor of phosphodiesterase 4 (PDE4). It can be combined with formoterol to enhance the antiinflammatory effect of dexamethasone.
More Information Supplier Page
Roflumilast N-oxide, an active metabolite of roflumilast, is an inhibitor of phosphodiesterase 4 (PDE4). It can be combined with formoterol to enhance the antiinflammatory effect of dexamethasone.
More Information Supplier Page
Roflumilast N-oxide, an active metabolite of roflumilast, is an inhibitor of phosphodiesterase 4 (PDE4). It can be combined with formoterol to enhance the antiinflammatory effect of dexamethasone.
More Information Supplier Page
Roflumilast N-oxide, an active metabolite of roflumilast, is an inhibitor of phosphodiesterase 4 (PDE4). It can be combined with formoterol to enhance the antiinflammatory effect of dexamethasone.
More Information Supplier Page
Eprobemide is a reversible monoamine oxidase A inhibitor and is classified as a drug for depression.
More Information Supplier Page
Eprobemide is a reversible monoamine oxidase A inhibitor and is classified as a drug for depression.
More Information Supplier Page
Eprobemide is a reversible monoamine oxidase A inhibitor and is classified as a drug for depression.
More Information Supplier Page